구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL |
Overview Company | AstraZeneca |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Malignant Glioma; Glioblastoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target of rapamycin pathway |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse, xenografts, co-administrat |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse, xenografts, co-administrat |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer.. Resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies remains a challenge in HER2-positive breast cancer. We evaluated whether aspirin could enhance the activity of lapatinib, a HER2/EGFR tyrosine kinase inhibitor, in HER2-positive breast cancer models. In BT-474 and SK-BR-3 cells, as… |
Clinical Safety signal | Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer.. Resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies remains a challenge in HER2-positive breast cancer. We evaluated whether aspirin could enhance the activity of lapatinib, a HER2/EGFR tyrosine kinase inhibitor, in HER2-positive breast cancer models. In BT-474 and SK-BR-3 cells, as… |
Clinical Reported ORR | 0% |
Clinical Reported PFS | 1.41 |
Clinical Reported OS | 14.09 |
Clinical Result source | ClinicalTrials.gov NCT03321981 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03321981 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL |
Overview Company | AstraZeneca |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Malignant Glioma; Glioblastoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target of rapamycin pathway |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse, xenografts, co-administrat |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse, xenografts, co-administrat |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer.. Resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies remains a challenge in HER2-positive breast cancer. We evaluated whether aspirin could enhance the activity of lapatinib, a HER2/EGFR tyrosine kinase inhibitor, in HER2-positive breast cancer models. In BT-474 and SK-BR-3 cells, as… |
Clinical Safety signal | Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer.. Resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies remains a challenge in HER2-positive breast cancer. We evaluated whether aspirin could enhance the activity of lapatinib, a HER2/EGFR tyrosine kinase inhibitor, in HER2-positive breast cancer models. In BT-474 and SK-BR-3 cells, as… |
Clinical Reported ORR | 0% |
Clinical Reported PFS | 1.41 |
Clinical Reported OS | 14.09 |
Clinical Result source | ClinicalTrials.gov NCT03321981 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03321981 |
추천 비교
추천 비교